Vir Biotechnology Inc (VIR) - News Archive

In the evolving landscape of hepatitis B treatment, the glimmer of hope shines brighter than ever, thanks to the recent findings from Vir Biotechnology, Inc.’s MARCH Phase 2 clinical study. Based in the vibrant city of...

Vir Biotechnology Showcases Promising Advances in Hepatitis Treatments at J.P. Morgan Healthcare Conference Vir Biotechnology Inc. (NASDAQ: VIR) has announced its participation in the upcoming 43rd Annual J.P. Morgan He...

Vir Biotechnology s Bold Steps: Navigating the Landscape of T-Cell Engagers and Chronic Hepatitis B Treatments In the ever-evolving realm of biotechnology, Vir Biotechnology, Inc. is making waves with two significant de...

Advancing the Frontier of Hepatitis Treatment: Vir Biotechnology s Breakthroughs in Clinical TrialsIn a groundbreaking development for the treatment of viral hepatitis, Vir Biotechnology, Inc. (NASDAQ: VIR) has reported...

Tipping the Scale: Vir Biotechnology Advances Toward a Cure for Chronic Hepatitis BIn an era marked by remarkable advancements in biotechnology, Vir Biotechnology, Inc. (NASDAQ: VIR) has emerged as a beacon of hope for...

In a significant stride toward effective treatments for chronic hepatitis B (HBV), Vir Biotechnology, Inc. (Nasdaq: VIR) has announced promising end-of-treatment results from the MARCH Phase 2 clinical study during the...

Title : A Ray of Hope: New Combinations Show Promise in Battling Chronic Hepatitis BIn the quest for effective treatments against chronic hepatitis B, researchers and patients alike have long awaited breakthroughs that...

Vir Biotechnology Announces Closure of Exclusive Licensure with Sanofi for Advanced T-Cell Engagers SAN FRANCISCO Vir Biotechnology, Inc. (Nasdaq: VIR) has officially closed its exclusive worldwide license agreement wit...

: Vir Biotechnology, Inc. has recently entered into an exclusive worldwide license agreement with Sanofi concerning the development of clinical-stage T-cell engagers (TCEs), a promising class of immunotherapeutic agents...

The pursuit of advancing immunotherapy is a cornerstone of modern oncology and infectious disease treatment modalities. In this landscape, Vir Biotechnology, Inc. (Nasdaq: VIR) has made significant strides through its s...

Vir Biotechnology, Inc. (Nasdaq: VIR) has announced that it will be releasing its financial results for the second quarter of 2024 on August 1, 2024. The results will be accessible to the public on the company s website...

SAN FRANCISCO The biotech industry received significant news from Vir Biotechnology, Inc. (Nasdaq: VIR) today, as the U.S. Food and Drug Administration (FDA) has both cleared the company s investigational new drug (IND)...